Domen, C.H., Sillau, S. Liu, Y., Adkins, M., Rajkovic, S., Bainbridge, J., Sempio, C., Klawitter, J., & Leehey, M.A. (2023). Cognitive safety data from a randomized, double-blind, parallel-group, placebo-controlled phase IIb study of the effects of a cannabidiol and ?9-tetrahydrocannabinol drug on Parkinson disease-related motor symptoms. Movement Disorders, 38, 1341-1346. https://doi.org/10.1002/mds.29447
Holden, S.K., Domen, C.H., Sillau, S., Liu, Y., Leehey, M.A. (2022). Higher risk, higher reward? Self-reported effects of real-world cannabis use in Parkinson’s disease. Movement Disorders Clinical Practice, 9, 340-350. https://doi.org/10.1002/mdc3.13414
Domen CH, Collins RL, Davis JJ. The APPCN multisite didactic initiative: Development, benefits, and challenges. Clin Neuropsychol. 2021 Jan;35(1):115-132. PubMed PMID: 32615854
Wodushek TR, Domen CH. Comparing two models of performance validity assessment in patients with Parkinson's disease who are candidates for deep brain stimulation surgery. Appl Neuropsychol Adult. 2020 Jan-Feb;27(1):9-21. PubMed PMID: 30183361
Domen CH, Collins RL, Davis JJ. The APPCN multisite didactic initiative: Development, benefits, and challenges. Clin Neuropsychol. 2020 Jul 2;:1-18. [Epub ahead of print] PubMed PMID: 32615854
Domen CH, Greher MR, Hosokawa PW, Barnes SL, Hoyt BD, Wodushek TR. Are Established Embedded Performance Validity Test Cut-Offs Generalizable to Patients With Multiple Sclerosis?. Arch Clin Neuropsychol. 2020 Jul 24;35(5):511-516. PubMed PMID: 32186676
Wodushek TR, Domen CH. Comparing two models of performance validity assessment in patients with Parkinson's disease who are candidates for deep brain stimulation surgery. Appl Neuropsychol Adult. 2020 Jan-Feb;27(1):9-21. PubMed PMID: 30183361
Domen CH, Shrestha A, Chapman K, Drees C. The impact of cannabis use on intracarotid amobarbital testing. Epilepsy Behav Rep. 2019;12:100328. PubMed PMID: 31497755